NALIRIFOX versus gemcitabine plus nab-paclitaxel in Chinese patients with advanced pancreatic adenocarcinoma: a randomized, open-label phase II trial

Journal:

Nature Communications

Published:

2026-01-16

DOI:

10.1038/s41467-026-68409-0

Affiliations:

23

Authors:

36

Go to article

Institutions	Authors	Share
State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, China	11.000000 11.000000	0.31
CSPC Pharmaceutical Group, China	4.000000	0.11
Harbin Medical University Cancer Hospital, China	1.000000	0.03
The First Hospital of China Medical University, China	1.000000	0.03
Liaoning Cancer Hospital and Institute, China	1.000000	0.03
Wuhan Union Hospital, HUST, China	1.000000	0.03
Jinan Central Hospital, China	1.000000	0.03
Cancer Hospital of Yunnan Province, China	1.000000	0.03
The First Affiliated Hospital of Bengbu Medical University, China	1.000000	0.03
No.1 Hospital of Shanxi Medical University, SXMU, China	1.000000	0.03
Sun Yat-sen Memorial Hospital, SYSU, China	1.000000	0.03
Cangzhou Central Hospital, China	1.000000	0.03
Fujian Cancer Hospital, China	1.000000	0.03
Affiliated Hospital of Hebei University, HBU, China	1.000000	0.03
Jiangxi Provincial Cancer Hospital, China	1.000000	0.03
Tongji Hospital (TJH), HUST, China	1.000000	0.03
The First Affiliated Hospital of Chongqing Medical University, China	1.000000	0.03
Changzhi People's Hospital, China	1.000000	0.03
The Second Clinical Hospital of Jilin University, China	1.000000	0.03
Shandong Cancer Hospital, China	1.000000	0.03
Hunan Provincial People's Hospital, China	1.000000	0.03
The General Hospital, TMU, China	1.000000	0.03
Peking University First Hospital, PKUHSC, China	1.000000	0.03

Interested in Oncology and Carcinogenesis?